Alexander I Damanakis
Overview
Explore the profile of Alexander I Damanakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lyu S, Fretter C, Simon A, Spielmann S, Damanakis A, Zhao Y, et al.
Transl Oncol
. 2024 Jun;
47:102044.
PMID: 38917592
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis, wherefore targeted therapies have experienced increasing interest. Zolbetuximab is a novel targeted therapy under investigation in patients with PDAC and...
2.
Braxton A, Kiemen A, Grahn M, Forjaz A, Parksong J, Babu J, et al.
Nature
. 2024 May;
629(8012):679-687.
PMID: 38693266
Pancreatic intraepithelial neoplasias (PanINs) are the most common precursors of pancreatic cancer, but their small size and inaccessibility in humans make them challenging to study. Critically, the number, dimensions and...
3.
Knipper K, Hussein Y, Simon A, Fretter C, Damanakis A, Zhao Y, et al.
J Cancer Res Clin Oncol
. 2024 Mar;
150(3):137.
PMID: 38502354
Purpose: Patients with pancreatic ductal adenocarcinoma (PDAC) have yet to experience significant benefits from targeted therapy. Olaparib is currently the only active substance in BRCA-mutated PDACs that successfully influences the...
4.
Knipper K, Damanakis A, Lyu S, Simon A, Wahler I, Bruns C, et al.
BMC Cancer
. 2023 Jul;
23(1):669.
PMID: 37461005
Background: Patients diagnosed with esophageal cancer demonstrate a low overall survival even despite the established multimodal therapy as the current standard of care. Therefore, further biomarkers for patients with high-risk...
5.
Knipper K, Damanakis A, Zhao Y, Bruns C, Schmidt T, Popp F, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046710
Purpose: The pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancer entities. Effective therapy options are still lacking. The tumor microenvironment possibly bears further treatment possibilities. This study...
6.
Lyu S, Krey T, Damanakis A, Zhao Y, Bruns C, Schmidt T, et al.
J Cancer Res Clin Oncol
. 2023 Mar;
149(10):7539-7546.
PMID: 36971797
Purpose: Rising incidence of pancreatic ductal adenocarcinoma (PDAC) bind with insufficient therapy options showcases a great medical challenge. Further biomarkers are required to identify patients, who will benefit from more...
7.
Braxton A, Kiemen A, Grahn M, Forjaz A, Babu J, Zheng L, et al.
bioRxiv
. 2023 Feb;
PMID: 36747709
Pancreatic intraepithelial neoplasia (PanIN) is a precursor to pancreatic cancer and represents a critical opportunity for cancer interception. However, the number, size, shape, and connectivity of PanINs in human pancreatic...
8.
Knipper K, Lyu S, Goebel H, Damanakis A, Zhao Y, Bruns C, et al.
J Cancer Res Clin Oncol
. 2022 Dec;
149(9):5531-5538.
PMID: 36472768
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is currently one of the leading causes of cancer death worldwide. Therefore, building further subgroups as well as enabling individual patient therapy and diagnostics are...
9.
Damanakis A, Wahler I, Fuchs H, Loser H, Schroder W, Zander T, et al.
Sci Rep
. 2022 Dec;
12(1):20745.
PMID: 36456612
Today, individual prognosis in patients with adenocarcinoma of the esophagus (EAC) is based on post-surgical TNM staging and valid biomarkers are still not implemented. Integrin beta1 (ITGB1) is widely expressed...
10.
Damanakis A, Toader J, Wahler I, Plum P, Quaas A, Ernst A, et al.
Br J Surg
. 2022 May;
109(8):746-753.
PMID: 35574811
Background: Recent findings support the hypothesis of sex-related differences in inflammatory and immunological responses to trauma. The aim of this study was to address sex-specific aspects in patients who underwent...